Company profile for Ray Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Ray Therapeutics is developing novel optogenetics gene therapies for patients with blinding diseases. The company is developing its lead candidate Ray-001 in retinitis pigmentosa, a degenerative retinal disease with significant unmet medical need. The company’s mission is to use optogenetics to restore vision, independent of genetic mutation for patients with inherited retinal diseases. Ray Therapeutics is based in San Diego...
Ray Therapeutics is developing novel optogenetics gene therapies for patients with blinding diseases. The company is developing its lead candidate Ray-001 in retinitis pigmentosa, a degenerative retinal disease with significant unmet medical need. The company’s mission is to use optogenetics to restore vision, independent of genetic mutation for patients with inherited retinal diseases. Ray Therapeutics is based in San Diego, CA. Restore vision in patients with retinitis pigmentosa and other degenerative retinal diseases with our novel optogenetics approach.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
San Diego, California
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250423701322/en/Ray-Therapeutics-Awarded-%248M-CIRM-Grant-to-Advance-RTx-015-Gene-Therapy-for-Retinitis-Pigmentosa

BUSINESSWIRE
24 Apr 2025

https://www.businesswire.com/news/home/20241017147331/en

BUSINESSWIRE
17 Oct 2024

https://www.businesswire.com/news/home/20240916597363/en

BUSINESSWIRE
16 Sep 2024
Ray Therapeutics Receives $4M in Funding
Ray Therapeutics Receives $4M in Funding

13 Nov 2023

// BUSINESSWIRE

https://www.businesswire.com/news/home/20231113394654/en

BUSINESSWIRE
13 Nov 2023

https://www.businesswire.com/news/home/20230821437345/en

BUSINESSWIRE
21 Aug 2023

https://www.globenewswire.com/news-release/2023/06/12/2686245/32452/en/Adverum-Biotechnologies-Grants-License-to-Ray-Therapeutics-Inc-for-the-AAV-7m8-Intravitreal-Capsid.html

GLOBENEWSWIRE
12 Jun 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty